Moustafa M. Abdelaziz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Moustafa M. Abdelaziz has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Huan Gong
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
5 shared publications - Marcus Laird Forrest
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
5 shared publications - Islam Ahmed Khalil
Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University of Science and Technology (MUST), Giza 12582, Egypt
3 shared publications - Amr Hefnawy
Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, TX 78712, USA
2 shared publications - Asem Anter
Microbiology Unit, Drug Factory, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), P.O. Box 77, Giza 12566, Egypt
2 shared publications - Chad Groer
Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA
2 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (12)
Impact of oxidative degradation on the bioavailability of subcutaneously administered adalimumab
- 17 October 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (12)
Open AccessImpact of oxidative degradation on the bioavailability of subcutaneously administered adalimumab
- Open Access
- 17 February 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 222, 115025
Magnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples
- 17 February 2026
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 222, 115025
Open AccessMagnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples
- 7 February 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 692, 126659
Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths
- 7 February 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 692, 126659
Lyophilized formulation development and characterization of stable glatiramer acetate/oligonucleotide polyplexes at clinically therapeutic strengths
- Open Access
- 28 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
Development of long-acting formulations for hydrophobic Kifunensine analogues as potent inhibitors of type I mannosidase enzymes
- 28 November 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
Open AccessDevelopment of long-acting formulations for hydrophobic Kifunensine analogues as potent inhibitors of type I mannosidase enzymes
- 1 November 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 6323-6338
Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity
Unmethylated cytosine-guanine oligodeoxynucleotides (CpG ODNs) have a storied history as agonists for Toll-like receptor 9 (TLR9). CpG ODNs have shown promising antitumor effects in preclinical studies by inducing potent proinflammatory immune responses. However, clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure to CpG ODNs. We previously identified that glatiramer acetate (GA), an FDA-approved, lysine-rich polypeptide, could complex class B CpG into cationic nanoparticles which persist at the intratumoral injection site while mitigating the induction of systemic proinflammatory cytokines in mouse tumor models. To extend GA applications across subtypes of CpG ODN (class A, B, and C), we evaluated physiochemical properties and identified the immunological signaling of GA and its complexes with different classes of CpG ODNs. We compared the physiochemical characteristics of three types of GA-CpG nanoparticles, followed by assessments of cell uptake efficiency and endolysosomal trafficking. We then performed successive in vitro and in vivo assays to evaluate immunological discrepancies. Complexation with GA preserved the immunological activity of CpG ODN subtypes while encapsulating them into cationic spherical nanoparticles. GA improved the cellular uptake of CpG ODNs, generally increased retention in early endosomes, and amplified immunological responses. A subsequent in vivo experiment confirmed the achievement of potent tumor suppression while mitigating systemic immune-related toxicities. Together, these data help elucidate the noncanonical role of GA to serve as a nucleic acid delivery scaffold that can improve the efficacy and safety of CpG adjuvant for clinical cancer immunotherapy.
- 1 November 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (12) , 6323-6338
Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity
Unmethylated cytosine-guanine oligodeoxynucleotides (CpG ODNs) have a storied history as agonists for Toll-like receptor 9 (TLR9). CpG ODNs have shown promising antitumor effects in preclinical studies by inducing potent proinflammatory immune responses. However, clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure to CpG ODNs. We previously identified that glatiramer acetate (GA), an FDA-approved, lysine-rich polypeptide, could complex class B CpG into cationic nanoparticles which persist at the intratumoral injection site while mitigating the induction of systemic proinflammatory cytokines in mouse tumor models. To extend GA applications across subtypes of CpG ODN (class A, B, and C), we evaluated physiochemical properties and identified the immunological signaling of GA and its complexes with different classes of CpG ODNs. We compared the physiochemical characteristics of three types of GA-CpG nanoparticles, followed by assessments of cell uptake efficiency and endolysosomal trafficking. We then performed successive in vitro and in vivo assays to evaluate immunological discrepancies. Complexation with GA preserved the immunological activity of CpG ODN subtypes while encapsulating them into cationic spherical nanoparticles. GA improved the cellular uptake of CpG ODNs, generally increased retention in early endosomes, and amplified immunological responses. A subsequent in vivo experiment confirmed the achievement of potent tumor suppression while mitigating systemic immune-related toxicities. Together, these data help elucidate the noncanonical role of GA to serve as a nucleic acid delivery scaffold that can improve the efficacy and safety of CpG adjuvant for clinical cancer immunotherapy.
- 15 August 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (11) , 3145-3172
Recent advances in nano-based drug delivery systems for treatment of liver cancer
- 15 August 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (11) , 3145-3172
Recent advances in nano-based drug delivery systems for treatment of liver cancer
- 3 January 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 80
Inhalable vancomycin-loaded lactose microparticles for treatment of MRSA pneumonia
- 3 January 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 80
Inhalable vancomycin-loaded lactose microparticles for treatment of MRSA pneumonia
- Open Access
- 16 August 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (34) , 30161-30170
Silica-Coated Magnetic Nanoparticles for Vancomycin Conjugation
Drug resistance is a global health challenge with thousands of deaths annually caused by bacterial multidrug resistance (MDR). Efforts to develop new antibacterial molecules do not meet the mounting needs imposed by the evolution of MDR. An alternative approach to overcome this challenge is developing targeted formulations that can enhance the therapeutic efficiency and limit side effects. In this aspect, vancomycin is a potent antibacterial agent that has inherent bacterial targeting properties by binding to the D-Ala-D-Ala moiety of the bacterial peptidoglycan. However, the use of vancomycin is associated with serious side effects that limit its clinical use. Herein, we report the development of vancomycin-conjugated magnetic nanoparticles using a simple conjugation method for targeted antibacterial activity. The nanoparticles were synthesized using a multistep process that starts by coating the nanoparticles with a silica layer, followed by binding an amide linker and then binding the vancomycin glycopeptide. The developed vancomycin-conjugated magnetic nanoparticles were observed to exhibit a spherical morphology and a particle size of 16.3 ± 2.6 nm, with a silica coating thickness of 5 nm and a total coating thickness of 8 nm. The vancomycin conjugation efficiency on the nanoparticles was measured spectrophotometrically to be 25.1%. Additionally, the developed formulation retained the magnetic activity of the nanoparticles, where it showed a saturation magnetization value of 51 emu/g, compared to 60 emu/g for bare magnetic nanoparticles. The in vitro cell biocompatibility demonstrated improved safety where vancomycin-conjugated nanoparticles showed IC50 of 183.43 μg/mL, compared to a much lower value of 54.11 μg/mL for free vancomycin. While the antibacterial studies showed a comparable activity of the developed formulation, the minimum inhibitory concentration was 25 μg/mL, compared to 20 μg/mL for free vancomycin. Accordingly, the reported formulation can be used as a platform for the targeted and efficient delivery of other drugs.
- 16 August 2022
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 7 (34) , 30161-30170
Open AccessSilica-Coated Magnetic Nanoparticles for Vancomycin Conjugation
Drug resistance is a global health challenge with thousands of deaths annually caused by bacterial multidrug resistance (MDR). Efforts to develop new antibacterial molecules do not meet the mounting needs imposed by the evolution of MDR. An alternative approach to overcome this challenge is developing targeted formulations that can enhance the therapeutic efficiency and limit side effects. In this aspect, vancomycin is a potent antibacterial agent that has inherent bacterial targeting properties by binding to the D-Ala-D-Ala moiety of the bacterial peptidoglycan. However, the use of vancomycin is associated with serious side effects that limit its clinical use. Herein, we report the development of vancomycin-conjugated magnetic nanoparticles using a simple conjugation method for targeted antibacterial activity. The nanoparticles were synthesized using a multistep process that starts by coating the nanoparticles with a silica layer, followed by binding an amide linker and then binding the vancomycin glycopeptide. The developed vancomycin-conjugated magnetic nanoparticles were observed to exhibit a spherical morphology and a particle size of 16.3 ± 2.6 nm, with a silica coating thickness of 5 nm and a total coating thickness of 8 nm. The vancomycin conjugation efficiency on the nanoparticles was measured spectrophotometrically to be 25.1%. Additionally, the developed formulation retained the magnetic activity of the nanoparticles, where it showed a saturation magnetization value of 51 emu/g, compared to 60 emu/g for bare magnetic nanoparticles. The in vitro cell biocompatibility demonstrated improved safety where vancomycin-conjugated nanoparticles showed IC50 of 183.43 μg/mL, compared to a much lower value of 54.11 μg/mL for free vancomycin. While the antibacterial studies showed a comparable activity of the developed formulation, the minimum inhibitory concentration was 25 μg/mL, compared to 20 μg/mL for free vancomycin. Accordingly, the reported formulation can be used as a platform for the targeted and efficient delivery of other drugs.